Challenges and potential barriers to the uptake of antiretroviral-based prevention in Asia and the Pacific region

Sexual Health

Volumn 11, Issue 2, 2014, Pages 126-136

  Lo, Ying Ru ^a   Kato, Masaya ^a   Phanuphak, Nittaya ^b   Fujita, Masami ^a   Duc, Duong Bui ^c   Sopheap, Seng ^d   Pendse, Razia ^a   Yu, Dongbao ^a   Wu, Zunyou ^e   Chariyalertsak, Suwat ^f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c MINISTRY OF HEALTH   (Viet Nam)

^d Ministry of Health Cambodia   (Cambodia)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Cambodia; China; pre exposure prophylaxis; Thailand; treatment as prevention; Vietnam

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA SOUTH OF THE SAHARA; ASIA; CAMBODIA; CHINA; CLINICAL TRIAL (TOPIC); DISEASE SURVEILLANCE; DRUG SURVEILLANCE PROGRAM; EPIDEMIC; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY; POPULATION; PROPHYLAXIS; REVIEW; THAILAND; VIET NAM; VIRUS TRANSMISSION;

EID: 84904340119     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH13094     Document Type: Review

References (113)

1. United Nations Joint Programme on HIV/AIDS (UNAIDS). HIV in Asia and the Pacific. UNAIDS report 2013. Geneva: UNAIDS; 2013. Available online at: http://www.unaids.org/en/resources/documents/ 2013/name,89768,en.asp [verified1 June 2014].
2. United Nations Joint Programme on HIV/AIDS (UNAIDS). UNAIDS terminology guidelines. Geneva: UNAIDS; 2011. Available online at: http://www.unaids.org/en/ media/unaids/content assets/documents/document/2011/20111009-UNAIDS-Terminology- Guidelines-MidtermAdditions-en.pdf [verified June 2014].
3. World Health Organization Regional Office for the Western Pacific. HIV and sexually transmitted infections in the Western Pacific region 2000-2010. Manila: World Health Organization; 2012. Available online at: http://www.wpro.who.int/publications/2012/document- hiv-and-sti-2000-2010.pdf [verified September 2012].
4. World Health Organization Regional Office for South-East Asia. HIV/AIDS in the South-East Asia region progress report 2011. New Delhi: World Health Organization; 2012.
5. United Nations Joint Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS; 2013. Available online at: http://www.unaids.org/en/ media/unaids/contentassets/documents/epidemiology/ 2013/gr2013/ UNAIDS-Global-Report-2013-en.pdf [verified 2 June 2014].
6. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505. doi:10.10 56/NEJMoa1105243
7. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV- 1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-94. doi:10.1097/00126334-200204150-00009
8. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-99. doi:10.1056/ NEJMoa1011205
9. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410. doi:10.1056/ NEJMoa1108524
10. World Health Organization (WHO). Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva: WHO; 2012.
11. Ping LH, Jabara CB, Rodrigo AG, Hudelson SE, Piwowar-Manning E, Wang L, et al. HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. PLoS ONE 2013; 8: e71557. doi:10.1371/ journal.pone.0071557
12. Cohen J. Breakthrough of the year. HIV treatment as prevention. Science 2011; 334: 1628. doi:10.1126/science.334.6063.1628
13. Grinsztejn B, Ribaudo H, Cohen MS, Swindells S, Badel-Faesen S, Burns D, et al. Effects of early versus delayed initiation of antiretroviral therapy (ART) on HIV clinical outcomes: results from the HPTN 052 randomized clinical trial. Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy. Geneva: International AIDS Society 2011. Abstract No. MOAX0105.
14. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a clusterrandomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials 2014; 15: 57. doi:10.1186/1745-6215-15-57
15. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (treatment as prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials 2013; 14: 230. doi:10.1186/1745-6215-14-230
16. Boily MC, Masse B, Alsallaq R, Padian NS, Eaton JW, Vesqua JF, et al. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 2012; 9: e1001250. doi:10. 1371/journal.pmed.1001250
17. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 2011; 9: 446-69. doi:10.2174/ 157016211798038597
18. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376: 532-9. doi:10.1016/S0140-6736(10) 60936-1
19. Das M, Chu PL, Santos GM, Scheer S, Vittinghof E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010; 5: e11068. doi:10.1371/journal.pone. 0011068
20. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011; 8: CD009153.
21. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339: 966-71. doi:10.1126/science. 1228160
22. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57. doi:10.1016/S0140- 6736(08)61697-9
23. Kato M, Granich R, Bui DD, Tran HV, Nadol P, Jacka D, et al. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. J Acquir Immune Defic Syndr 2013; 63: e142-9. doi:10.1097/QAI.0b013e31829b535b
24. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis 2011; 52: 1046-9. doi:10.1093/cid/cir085
25. Cohen MS, Holmes C, Padian N, Wolf M, Hirnschall G, Lo YR, et al. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. Health Aff 2012; 31: 1439-49. doi:10.1377/hlthaff.2012.0250
26. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Rockville: Department of Health and Human Services; 2012. Available online at: http://www.aidsinfo. nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [verified June 2013].
27. World Health Organization (WHO). Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach., Geneva: WHO; 2012. Available online at: http://www.who.int/hiv/pub/guidelines/ 9789241501972/en/ [verified1 June 2014].
28. Gupta S, Granich R, Suthar AB, Smyth C, Baggaley R, Sculier D, et al. Global policy review of antiretroviral therapy eligibility criteria for treatment and prevention of HIV and tuberculosis in adults, pregnant women, and serodiscordant couples. J Acquir Immune Defic Syndr 2013; 62: e87-97. doi:10.1097/QAI.0b013e318 27e4992
29. National Center for HIV/AIDS Dermatology and STD (NCHADS). Concept note on treatment as prevention (TasP) as a strategy for elimination of new HIV infections in Cambodia. Phnom Penh: NCHADS; 2012. Available online at: http://www.nchads.org/AIDS% 20Care/TasP-NCHADS%20Concept%20Note-25-Dec-2012-eng. pdf [verified March 2014].
30. Zhang L, Chow EP, Jing J, Zhuang X, Li X, He M, et al. HIV prevalence in China: integration of surveillance data and a systematic review. Lancet Infect Dis 2013; 13: 955-63. doi:10.1016/S1473-30 99(13)70245-7
31. Zhang L, Gray RT, Wilson DP. Modelling the epidemiological impact of scaling up HIV testing and antiretroviral treatment in China. Sex Health 2012; 9: 261-71. doi:10.1071/SH11104
32. HIV and AIDS Data Hub For Asia-Pacific. Ending AIDS in Thailand. Geneva: United Nations Joint Programme on HIV/ AIDS; 2013. Available online at: http://www.aidsdatahub.org/ sites/default/files/publication/Thailand-Ending- AIDS-2013fin.pdf [verified March 2014].
33. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-99. doi:10. 1056/NEJMoa1011205
34. Division of AIDS, National Institutes of Health (NIH). iPrEx OLE. Bethesda: NIH; 2011. Available online at: http://www.iprex ole.com/1pages/ aboutus/aboutus-whatisiprexole.php [verified June 2013].
35. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410. doi:10.1056/ NEJMoa1108524
36. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE. TDF2 Study Group Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367: 423-34. doi:10.1056/NEJMoa1110711
37. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, on behalf of the VOICE Study Team. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Boston, MA; San Francisco: International Antiviral Society - USA; 2013. Abstract 26LB.
38. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J. FEMPrEP Study Group Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367: 411-22. doi:10.1056/NEJ Moa1202614
39. Van der Straten A. Divergent adherence estimates with pharmacokinetic and behavioral measures in VOICE (MTN003). CROI 2014; 2014: 3-6.
40. Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, et al. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: implications for drug disposition in HIV prevention. J Clin Pharmacol 2014; 54: 574-83. doi:10.1002/ jcph.248
41. Thompson CG, Cohen MS, Kashuba AD. Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr 2013; 63: S240-7. doi:10.1097/QAI. 0b013e3182986ff8
42. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoowong R. Bangkok Tenofovir Study Group Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS ONE 2011; 6: e25127. doi:10.1371/journal.pone.0025127
43. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase3 trial. Lancet 2013; 381: 2083-90. doi:10.1016/ S0140-6736(13)61127-7
44. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376: 285-301. doi:10.1016/S0140-6736(10) 60742-8
45. Baral SD, Strömdahl S, Beyrer C. The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Curr Opin HIV AIDS 2012; 7: 563-8. doi:10.1097/COH.0b013e32 8358e49e
46. Srikantiah P, Ghidinelli M, Bachani D, Chasombat S, Daoni E, Mustikawati DE, et al. Scale-up of national antiretroviral therapy programs: progress and challenges in the Asia Pacific region. AIDS 2010; 24: S62-71. doi:10.1097/01.aids.0000390091 .45435.ea
47. World Health Organization (WHO). Progress report 2011: global HIV/AIDS response. Geneva: WHO; 2011. Available online at: http://www.who.int/hiv/pub/ progress-report2011/en/ [verified1 June 2014].
48. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-andtreat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52: 793-800. doi:10.1093/cid/ciq243
49. World Health Organization (WHO). Meeting report on framework for metrics to support effective treatment as prevention, 2-3 April 2012. Geneva: WHO; 2012. Available online at: http://www.who. int/hiv/pub/meetingreports/framework- metrics/en/ [verified1 June 2014].
50. Steen R, Zhao P, Wi TE, Punchihewa N, Abeyewickreme I, Lo YR. Halting and reversing HIV epidemics in Asia by interrupting transmission in sex work: experience and outcomes from ten countries. Expert Rev Anti Infect Ther 2013; 11: 999-1015. doi:10. 1586/14787210.2013.824717
51. National Centre for HIV/AIDS, Dermatology and STD. Estimations and projections of HIV/AIDS in Cambodia 2010-2015. Phnom Penh: Ministry of Health; 2011.
52. National Center for HIV/AIDS Dermatology and STD. Annual report 2012. Phnom Pehn: Ministry of Health; 2013. Available online at: http://www.nchads. org/Report/Annual%20report%2020 12en.pdf [verified March 2014].
53. World Health Organization Regional Office for the Western Pacific (WHOROWP). Joint review of the Cambodian National Health Sector Response to HIV 2013. Manila: WHOROWP; 2014.
54. National Center for HIV/AIDS. Dermatology and STD (NCHADS). Annual report 2011. Phnom Pehn: Ministry of Health; 2012. Available online at: http://www.nchads.org/Report/Annual%20 Report%202011%20Eng.pdf [verified March 2014].
55. National Centre for HIV/AIDS, Dermatology and STD (NCHADS). Conceptual framework for elimination of new HIV infections in Cambodia by 2020. Phnom Penh: Ministry of Health; 2012.
56. World Health Organization (WHO). The use of antiretroviral drugs for treating and preventing HIV infection. Geneva: WHO; 2013. Available online at: http://www.who.int/hiv/pub/guidelines/arv20 13/download/en/ [verified March 2014].
57. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M, et al. Five year outcomes of the China national free antiretroviral treatment program. Ann Intern Med 2009; 151: 241-51. doi:10.7326/0003-4819-151-4- 200908180-00006
58. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011; 11: 516-24. doi:10.1016/S1 473-3099(11)70097-4
59. Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet 2013; 382: 1195-203. doi:10.1016/S0140-6736(12)61898-4
60. Wang L, Peng Z, Li L, Norris JL, Wang L, Cao W, et al. HIV seroconversion and prevalence rates in heterosexual discordant couples in China: a systematic review and meta-analysis AIDS Care 2012; 24: 1059-70. doi:10.1080/09540121.2012. 661837
61. Zhao Y, Poundstone KE, Montaner J, Wu ZY. New policies and strategies to tackle HIV/AIDS in China. Chin Med J (Engl) 2012; 125: 1331-7.
62. Rou K, Sullivan SG, Liu P, Wu Z. Scaling up prevention programmes to reduce the sexual transmission of HIV in China. Int J Epidemiol 2010; 39(Suppl. 2): ii-38-46. doi:10.1093/ije/dyq211
63. Wu Z, Wang Y, Mao Y, Sullivan SG, Juniper N, Bulterys M. The integration of multiple HIV/AIDS projects into a coordinated national programme in China. Bull World Health Organ 2011; 89: 227-33. doi:10.2471/BLT.10.082552
64. Brown T, Peerapatanapokin W. The Asian Epidemic Model: a process model for exploring HIV policy and programme alternatives in Asia. Sex Transm Infect 2004; 80: i19-24. doi:10.11 36/sti.2004.010165
65. Family Health International (FHI) and Bureau of AIDS, TB and STIs, Department of Disease Control. The Asian Epidemic Model (AEM) projections for HIV/AIDS in Thailand: 2005-2025. Bangkok: Ministry of Public Health; 2008. Available online at: http://www.aidsdatahub.org/dmdocuments/The-Asian-Epidemic- Model-Projections-for-HIVAIDS-in-Thailand-2005-2025.pdf [verified March 2014].
66. Wheelock A, Eisingerich AB, Ananworanich J, Gomez GB, Hallett TB, Dybul MR, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS ONE 2013; 8: e54288. doi:10.1371/journal. pone.0054288
67. Viet Nam Authority of HIV/AIDS Control, Ministry of Health (VNAHAC). Viet Nam AIDS response progress report 2013. Hanoi: VNAHAC; 2013.
68. National Committee for AIDS (NCA). Drugs and prostitution prevention and control, Viet Nam AIDS response progress report 2012. Hanoi: NCA; 2012. Available online at: http://www.unaids. org/en/dataanalysis/knowyourresponse/ countryprogressreports/2012 countries/ce-VN-Narrative-Report.pdf [verified March 20014].
69. World Health Organization (WHO), Country Office for Vietnam. Good practice in Asia: targeted HIV prevention for IDU and sex workers. Viet Nam's first large-scale national harm reduction initiative. Hanoi: WHO; 2010. Available online at: http://www. who.int/hiv/pub/idu/wpro-vietnam/en/ [verified March 2014].
70. Fujita M, Poudel KC, Thi ND, Duc DB, Van KN, Green K, et al. A new analytical framework of 'continuumof prevention and care' to maximize HIV case detection and retention in care in Vietnam. BMC Health Serv Res 2012; 12: 483. doi:10.1186/1472-6963-12-483
71. Nguyen DB, Do NT, Shiraishi RW, Le YN, Tran QH, Nguyen HH, et al. Outcomes of antiretroviral therapy in Vietnam: results from a national evaluation. PLoS ONE 2013; 8: e55750. doi:10.1371/jour nal.pone.0055750
72. Maher L, Coupland H, Musson R. Scaling up HIV treatment, care and support for injecting drug users in Vietnam. Int J Drug Policy 2007; 18: 296-305. doi:10.1016/j.drugpo.2006.12.006
73. Do HM, Dunne MP, Kato M, Pham CV, Nguyen KV. Factors associated with suboptimal adherence to antiretroviral therapy in Viet Nam: a cross-sectional study using audio computer-assisted selfinterview (ACASI). BMC Infect Dis 2013; 13: 154. doi:10.1186/ 1471-2334-13-154
74. Results of the program evaluation of patients initiating antiretroviral therapy in two health facilities in Ho Chi Minh City, Viet Nam. Hanoi: Family Health International; 2010.
75. Jordan MR, La H, Nguyen HD, Sheehan H, Lien TT, Duong DV, et al. Correlates of HIV-1 viral suppression in a cohort of HIVpositive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS 2009; 20: 418-22. doi:10.1258/ijsa.2008. 008389
76. Bui DD, Mesquita F, Do TN, Kato M, Nguyen TTV, Nguyen TMT, et al. Treatment 2.0 pilot in Viet Nam: early progress and challenges. World J AIDS 2012; 2: 64-70. doi:10.4236/wja.2012.22009
77. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198: 687-93. doi:10.1086/ 590501
78. Pilcher CD, Eaton L, Kalichman S, Bisol C, de Souza Rda S. Approaching 'HIV elimination': interventions for acute HIV infection. Curr HIV/AIDS Rep 2006; 3: 160-8. doi:10.1007/s119 04-006-0011-4
79. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191: 1403-9. doi:10.1086/429411
80. Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary - will early infection compromise treatment-as-prevention strategies? PLoS Med 2012; 9: e1001232. doi:10.1371/journal.pmed.1001232
81. Jacquez JA, Koopman JS, Simon CP, Longini IM. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7: 1169-84.
82. Alam SJ, Romero-Severson E, Kim JH, Emond G, Koopman JS. Dynamic sex roles among men who have sex with men and transmissions from primary HIV infection. Epidemiology 2010; 21: 669-75. doi:10.1097/EDE.0b013e3181e9e901
83. Ananworanich J, Phanuphak N, de Souza M, Paris R, Arroyo M, Trichavaroj R, et al. Incidence and characterization of acute HIV-1 infection in a high-risk Thai population. J Acquir Immune Defic Syndr 2008; 49: 151-5. doi:10.1097/QAI.0b013e318183a96d
84. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE 2012; 7: e33948. doi:10.1371/journal. pone.0033948
85. Han X, Xu J, Chu Z, Dia D, Lu C, Wang X, et al. Screening acute HIV infections among Chinese men who have sex with men from voluntary counseling and testing centers. PLoS ONE 2011; 6: e28792. doi:10.1371/journal.pone.0028792
86. Yu D, Sutherland D, Ghidinelli M, Jordan MR. HIV drug resistance assessment in the Western Pacific Region. A systematic review. AIDS Rev 2011; 13: 214-26.
87. Sohn AH, Srikantiah P, Sungkanuparph S, Zhang F. Transmitted HIV drug resistance in Asia. Curr Opin HIV AIDS. 2013; 8: 27-33. doi:10.1097/COH. 0b013e32835b804f
88. Ibe S, Hattori J, Fujisaki S, Shigemi U, Fujisaki S, Shimizu K, et al. Trend of drug-resistant HIV type1 emergence among therapy-naive patients in Nagoya, Japan: an 8-year surveillance from 1999 to 2006. AIDS Res Hum Retroviruses 2008; 24: 7-14. doi:10.1089/aid.2007. 0129
89. Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, et al. Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance - HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2012; 41: 43-54. doi:10.1093/ije/ dyq192
90. Sungkanuparph S, Oyomopito R, Sirivichayakul S, Sirisanthana T, Li PCK, Kantipong P, et al. HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia studies to evaluate resistance-monitoring study. Clin Infect Dis 2011; 52: 1053-7. doi:10.1093/cid/cir107
91. Kiertiburanakul S, Chaiwarith R, Sirivichayakul S, Ditangco R, Jiamsakul A, Li PCK, et al. Comparisons of primary HIV-1 drug resistance between recent and chronic HIV-1 infection within a subregional cohort of Asian patients. PLoS ONE 2013; 8: e62057. doi:10.1371/journal.pone.0062057
92. Williams BG, Lima V, Gouws E. Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res 2011; 9: 367-82. doi:10.2174/157016211798038533
93. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19: 1-14. doi:10.1097/00002030-20 0501030-00001
94. Wagner BG, Blower S. Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs. PLoS ONE 2012; 7: e41212. doi:10.1371/journal.pone.0041 212
95. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24: 729-35. doi:10.1097/QAD.0b013e32833433fe
96. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, et al. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS 2010; 5: 298-304. doi:10.1097/COH.0b013e32 833a6c32
97. van Griensven F, Thienkrua W, McNicholl J, Wimonsate W, Chaikummao S, Chonwattana W, et al. Evidence of an explosive epidemic of HIV infection in a cohort of men who have sex with men in Thailand. AIDS 2013; 27: 825-32. doi:10.1097/QAD.0b0 13e32835c546e
98. Yang D, Chariyalertsak C, Wongthanee A, Kawichai S, Yotruean K, Saokhieo P, et al. Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. PLoS ONE 2013; 8: e76650. doi:10.1371/journal.pone. 0076650
99. World Health Organization (WHO) and National Institutes of Health. Informal consultation on antiretroviral treatment as HIV prevention: implementation science in Asia. Geneva: WHO; 2012. Available online at: http://www.who.int/hiv/pub/msm-meeting-report/en/ [verified1 June 2014].
100. Muessig KE, Smith MK, Powers KA, Lo YR, Burns DN, Grulich AE, et al. Does ART prevent HIV transmission among MSM? AIDS 2012; 26: 2267-73. doi:10.1097/QAD.0b013e328355713d
101. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9: 118-29. doi:10.1016/S1473-3099(09)70021-0
102. Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JC, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 2010; 24: 907-13. doi:10.1097/ QAD.0b013e3283372d90
103. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003; 169: 656-61.
104. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a metaanalysis. AIDS Behav 2010; 14: 731-47. doi:10.1007/s10461-008- 9489-7
105. Medley A, Baggaley R, Bachanas P, Cohen M, Shaffer N, Lo YR. Maximizing the impact of HIV prevention efforts: interventions for couples. AIDS Care 2013; 25: 1569-80. doi:10.1080/09540121. 2013.793269
106. World Health Organization (WHO), United Nations Office on Drugs and Crime, United Nations Joint Programme on HIV/ AIDS. Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users, 2012 revision. Geneva: WHO; 2012.
107. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Strathdee SA. 12 myths about HIV/AIDS and people who use drugs. Lancet 2010; 376: 208-11. doi:10.1016/S0140-6736(10)61005-7
108. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 2006; 41: 777-813. doi:10.1080/10826080600669579
109. Sineath RC, Finneran C, Sullivan P, Sanchez T, Smith DK, Griensven FV, et al. Knowledge of and interest in using preexposure prophylaxis for HIV prevention among men who have sex with men in Thailand. J Int Assoc Provid AIDS Care 2013; 12: 227-31. doi:10.1177/2325957413488184
110. Zhang Y, Peng B, She Y, Liang H, Peng HB, Qian HZ, et al. Attitudes toward HIV pre-exposure prophylaxis among men who have sex with men in western China. AIDS Patient Care STDS 2013; 27: 137-41. doi:10.1089/apc.2012.0412
111. Senn H, Wilton J, Sharma M, Fowler S, Tan D. Knowledge of and opinions on HIV pre-exposure prophylaxis among front-line service providers at Canadian AIDS service organizations. AIDS Res Hum Retroviruses 2013; 29: 1183-89. doi:10.1089/aid.2013.0090
112. World Bank. Population (total). Washington DC: World Bank; 2012. Available online at: http://data.worldbank.org/indicator/SP.POP. TOTL [verified June 2013].
113. Ministry of Health China. China AIDS Response Progress Report. 2012. Available online at: http://www.unaids.org/en/dataanalysis/ knowyourresponse/ countryprogressreports/2012countries/ce-CN- Narrative-Report[1].pdf [verified2 July 2014].